Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Current Deferred Revenue (2023 - 2025)

Ascentage Pharma Group International posted quarterly Current Deferred Revenue of $5.3 million for Q4 2025, up 1.28% year-on-year from $5.2 million in Q4 2024, and up 1.0% on a QoQ basis from $5.2 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 3 years of Current Deferred Revenue data on file, last reported at $5.3 million in Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue rose 1.28% year-over-year to $5.3 million; the trailing twelve-month figure through Dec 2025 stood at $5.3 million (up 1.28% YoY), and the FY2025 full-year result was $5.4 million, up 4.38% from the prior year.
  • Current Deferred Revenue for Q4 2025 stood at $5.3 million, up from $5.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $5.3 million in Q4 2023 and bottomed at $5.2 million in Q4 2024.
  • The 3-year median for Current Deferred Revenue is $5.3 million (2025), against an average of $5.3 million.
  • The widest annual swing landed in 2024, when Current Deferred Revenue dropped 2.18%; it then climbed 1.28% in 2025.
  • A 3-year view of Current Deferred Revenue shows it stood at $5.3 million in 2023, then declined by 2.18% to $5.2 million in 2024, then grew by 1.28% to $5.3 million in 2025.
  • The last three Current Deferred Revenue figures came in at $5.3 million (Q4 2025), $5.2 million (Q2 2025), and $5.2 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 5.29 Mn
Jun 30, 2025 5.23 Mn
Dec 31, 2024 5.22 Mn
Dec 31, 2023 5.33 Mn